Phase 4 Breast Cancer Trial, Recruiting NCT07695259 Sponsor: Wen-Ming Cao Condition: Breast Cancer
Back to Breast Cancer

Phase 4 Breast Cancer Trial, Recruiting

NCT07695259
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 60 years or older
  • People who have been newly diagnosed with invasive breast cancer in one breast only, confirmed by a tissue sample test
  • People whose cancer tests show HER-2 positive status (a specific protein found on cancer cells, confirmed by laboratory testing)
  • People whose cancer is at a specific stage — broadly described as stage II or IIIA, based on the size of the tumour and whether nearby lymph nodes are affected, but not spread to distant parts of the body (confirm exact staging details with the trial site)
  • People who have at least one measurable area of cancer that doctors can track during treatment
  • People who are generally able to carry out daily activities with no or only minor limitations (this is measured using a standard scale called the ECOG score of 0 or 1)
  • People whose blood test results show the blood cells and immune system are working within acceptable levels, without needing recent blood transfusions or growth factor treatments
  • People whose liver and kidney function blood test results are within acceptable ranges
  • People whose heart is pumping blood effectively, with the heart's pumping strength (called LVEF) measured at 50% or above
  • People who are willing to take part, sign a consent form, follow the study requirements, and attend follow-up appointments

Who may not be able to join:

  • People with certain specific types of breast cancer, including hidden (occult) breast cancer, inflammatory breast cancer, or a type affecting the skin around the nipple (eczematous carcinoma)
  • People with a known allergy to any ingredient in the study medication
  • People with serious heart problems that are expected to make chemotherapy unsafe, including certain abnormal heart rhythms, unstable chest pain (angina), significant heart valve disease, or evidence of a full-thickness heart attack on heart scans
  • People with severe or uncontrolled infections that could interfere with the study, including active hepatitis virus infection, HIV, lung infections, or similar conditions
  • People who have had another type of cancer in the past 5 years (some exceptions may apply, such as certain fully treated skin or cervical conditions — confirm with the trial site)
  • People who have taken part in another clinical trial within the 4 weeks before joining this study
  • People where the trial doctor believes there is any other reason participation would not be appropriate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +8613588054604

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Wen-Ming Cao
Registry
ClinicalTrials.gov
Start date
25 May 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological complete remission rate in breast cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov